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Abstract
Background: The indications for continuous oral anticoagulant treatment, the target interval and
the procedures for withdrawing treatment have changed in the last 10 years.
Methods: Patients on continuous oral anticoagulant treatment at the Outpatient Anticoagulant
Clinic at Umeå University Hospital in 2002 were included in a descriptive study (n = 900). 263 of
those had a mechanical heart valve prosthesis. Only patient records for patients with other
indications than mechanical heart valve prosthesis were examined. 582 of those records were
found. In the 55 remaining patients some clinical information was retrieved from the computerised
warfarin dosage database. These latter, more unsure clinical data, are presented separately.
Anticoagulant treatment was discontinued if lack of proper indication or presence of too high risk
for hemorrhagic complications were found.
Results: The prevalence of continuous oral anticoagulant treatment in the uptake area was 0.65%.
The most common target interval was INR 2.1–3.0, but patients with a mechanical heart valve
prosthesis were often treated more aggressively, i.e. with a higher INR target interval. Of the
patients on continuous treatment, 26.6% of the INR values were outside 2.0–3.0. The most
common reasons for oral anticoagulant treatment were atrial fibrillation or mechanical heart valve
prosthesis, in contrast to earlier findings in studies of our population in 1987 and 1990. We found
90 patients (10.0%) without proper indication for oral anticoagulant treatment or too high risk, and
their treatment was discontinued.
Conclusion:  In patients on oral anticoagulant therapy, re-evaluation of indications and risks
resulted in a substantial number of treatment withdrawals. There have been major changes in
treatment indications during the last decade, possibly due to rapid development of knowledge in
the field of thrombosis risk factors. Treatment should be re-considered once a year.
Background
Treatment with warfarin or other coumarin derivatives is
an established method of secondary prevention after
venous or arterial thromboembolic events, as well as for
primary prevention. In 1997 the prevalence of oral antico-
agulant treatment in Sweden was 0.8% [1]. That figure is
comparable with those in Denmark, were the prevalence
was 0.663% in 1997 and 0.784% in 1999 [2]. In 2002
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19,823 kDDD (thousand defined daily doses) of Waran®
2.5 mg tablets (sodium warfarin) were sold in Sweden. In
2003 the number rose to 21,387 kDDD. In 1998 Apeku-
marol® (dicoumarol) was withdrawn from the Swedish
market. Marcoumar® (phenprocoumon) can be prescribed
on licence when warfarin cannot be used [3]. Nearly all
patients now receive sodium warfarin in Sweden.
Oral anticoagulant treatment is a potentially dangerous
medication. According to a study in Mölndal, Sweden, 4.5
per 100 patient years resulted in a serious bleeding com-
plication leading to hospitalisation or persisting sequele.
0.5 per 100 patient years resulted in a patient dying of a
bleeding complication [4]. Because of the possibility of
serious, and sometimes lethal, complications it is neces-
sary to ensure that each patient has a valid indication for
continuous anticoagulant treatment. Every patient should
be re-evaluated yearly according to the Swedish National
Board of Health and Welfare.
In 1987–1990 a study compared the quality of oral anti-
coagulant treatment in the primary health care and in the
Department of Internal Medicine at Umeå University hos-
pital [5]. In 1990, 290 patients were treated in primary
health care and 175 via the Department of Internal Medi-
cine. Nowadays most patients in Umeå and the surround-
ing municipalities are treated via the specialized
Outpatient Anticoagulant Clinic within the Department
of Internal Medicine at Umeå University Hospital. Only a
few patients are managed through primary health care
centres.
The aims of this study were to describe patients on oral
anticoagulant therapy in our outpatient clinic, to compare
the results with a previous investigation, and re-evaluate
indications and risks of complications in these patients.
Methods
The cohort consisted of all patients receiving continuous
oral anticoagulant therapy with either warfarin or cou-
marin derivatives on October 15, 2002, registered at the
Outpatient Anticoagulant Clinic at the University Hospi-
tal of Umeå. It is the only hospital in the reception area. A
small number of patients treated by general practitioners
(n = 57) were not included in the study. In most cases
monitoring by general practitioners is due to long dis-
tances in our catchment area. Due to the same reason, it
may be estimated that the number of patients treated by
other hospitals is negligible. During the time of the study,
only one patient living in our area used a self-monitoring
device, and he was supervised by the Outpatient Anticoag-
ulant Clinic, and thus is included in our study.
All patients in the register with a treatment time defined
as "indefinite" were considered to be on continuous oral
anticoagulant therapy. The patient records from relevant
clinics were examined. Personal data, start date of antico-
agulant treatment, and all thromboembolic events in the
patient's history that came to our knowledge were
recorded. If previously unknown events were found in
personal communication with the patient, these events
were also recorded. For all patients without mechanical
heart valve prosthesis, the reason for the ongoing antico-
agulant treatment was recorded.
Mechanical valve prosthesis, dilated cardiomyopathia, or
venous thrombosis, in combination with one of the fol-
lowing coagulopathies, were defined as absolute indica-
tions for continuous warfarin treatment: antithrombin
deficiency, protein C deficiency, protein S deficiency,
homozygote for F V Leiden (FV 1691 AA), homozygote for
the prothrombin mutation (FII 20210 AA), heterozygote
for both APC-resistance (FV 1691 GA) and prothrombin
mutation (FII 20210 GA). If no problems with the treat-
ment were registered by the nurses at the Outpatient Anti-
Table 1: Indications for warfarin treatment in 1987, 1990 (both continuous and temporary) and 2002 (continuous) at the Department 
of Internal Medicine and primary health care units in the Umeå district. Data extracted from Jansson et al. [5]. Only one indication 
was recorded. Hierarchical order 1987 and 1990: pulmonary embolism, deep venous thrombosis, ischaemic cerebrovascular disease, 
peripheral thromboembolism, valvular heart disease, atrial fibrillation and miscellaneous. Hierarchical order 2002: valvular heart 
disease, atrial fibrillation, arterial thromboembolism, venous thromboembolism and miscellaneous. When a patient had both arterial 
and venous events, the most recent event decided the group. Patients with missing records are not included in the table.
Indications 1987 1990 2002
n (%) n (%) n (%)
Valvular heart disease 103 (42) 119 (41) 314 (37)
Arterial thromboembolism 70 (29) 82 (28) 11 (1)
Atrial fibrillation 18 (7) 21 (7) 339 (40)
Venous thromboembolism 47 (19) 52 (18) 60 (7)
Miscellaneous 5 (2) 16 (6) 120 (14)
Total 243 (100) 290 (100) 845 (100)Thrombosis Journal 2005, 3:20 http://www.thrombosisjournal.com/content/3/1/20
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coagulant Clinic, these patients were not subjected to any
further investigation in this study.
Patients with atrial fibrillation were divided into two
groups with low or high risk for cardioembolic events. A
patient with atrial fibrillation at low risk was defined one
who had none of the following: age more than 60 years,
previous cerebrovascular event, dilated cardiomyopathia,
mitral stenosis, marked mitral insufficiency, or marked
enlargement of the left atrium. All other patients with
atrial fibrillation were defined as high risk. High risk was
considered a legitimate reason for continuous anticoagu-
lant treatment as long as the risk for bleeding complica-
tions was considered low. Low risk patients were invited
for a medical examination, and discontinuation of antico-
agulant treatment was considered, with a possible switch
to other medications.
Patients with recurrent venous thromboses (three or
more) without known risk factors were offered a medical
examination and the presence of coagulopathy was exam-
ined. Anticoagulant treatment of these patients was con-
tinued if there were no contraindications.
All other legitimate indications were considered as relative
indications, and they were weighed against the risk of
bleeding complications. Risk factors and possible con-
traindications were: documented serious bleeding com-
plications, as well as factors increasing risk of bleeding
such as problems with compliance, fluctuating INR, bal-
ance problem with documented slip or fall accidents,
dementia, liver failure and high age (>85 years of age).
Patients with unclear indication or with known risk fac-
tors were invited for further investigation. The indication
for treatment was re-evaluated after laboratory tests and
medical examination was performed. If no valid indica-
tion was found, or if the risk was found to be too high,
anticoagulant treatment was discontinued or replaced
with other appropriate medication whenever possible.
INR was determined with STA® – SPA 50 kit (Diagnostica
Stago, Asnieres-sur-Seine, France) on a Sysmex® CA-6000
automatic coagulation instrument (Sysmex Corporation,
Kobe, Japan). In mid-November INR values for the sub-
jects were recorded. The first INR value dated on or after
October 15, 2002 was recorded. In absence of such a
value, the first INR value before this date was used. All val-
ues, except one, were determined within two months
before this date.
Demographic data was collected from the SCB, Statistics
Sweden website, http://www.ssd.scb.se/databaser/makro/
start.asp, accessed January 6, 2005.
Information about warfarin use in Sweden was retrieved
from the database PharmX supplied by Läkemedelsinfor-
mation AB.
Data was collected using a data sheet produced with SPSS
Data Entry Builder 3.0, and SPSS™ version 12.0 (SPSS inc,
Table 3: Treatment indications for patients with missing patient 
record, data retrieved from warfarin dosage database
Indication n %
Atrial fibrillation 30 55
Thrombosis NUD 11 20
Valvular disease NUD 5 9
Cerebrovascular disease 3 5
Biological heart valve prosthesis 3 5
Myocardial infarction 2 4
Cardiomyopathia 1 2
Total 55 100
Table 2: Indications for oral anticoagulant treatment, age of patient, duration of treatment, mean target and, actual INR October 15, 
2002. For mean target and INR, 10th and 90th percentiles are presented. All groups are compared with the Mechanical heart valve 
prosthesis group.
Indication n (%) Age (years) Duration of 
treatment (years)
Mean target (10–
90%)
INR mean (10–90%)
Mechanical heart valve 
prosthesis
263 (28.4) 68.3 7.43 2.59(2.55–2.85) 2.68(2.10–3.40)
Atrial fibrillation 399(44.3) 75.4 a 3.92 a 2.51 (2.40–2.55) a 2.54(1.90–3.20) c
Other 183(20.3) 65.3 n.s. 5.20 a 2.50 (2.25–2.55) a 2.50(1.90–3.20) b
Record missing d 55 (6.9) 70.9 n.s. 4.67 a 2.50(2.15–2.55) a 2.45 (1.83–3.10) n.s.
All indications 900 (100) 71.0 5.22 2.53 (2.40–2.55) 2.57 (1.90–3.20)
ap < 0.001, bp < 0.01, cp < 0.05, n.snonsignificant dcf. Table 3Thrombosis Journal 2005, 3:20 http://www.thrombosisjournal.com/content/3/1/20
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Chicago, IL, USA) was used for statistical analysis. For
comparison between groups, one-way ANOVA with Bon-
feroni post-hoc testing was used. A p-value <0.05 was con-
sidered statistically significant. All statistical tests and
corresponding p-values were two-sided.
Ethical permission was granted by the local ethical com-
mittee of Umeå University.
Results
We found 900 patients on continuous oral anticoagulant
medication at the Oral Anticoagulant Clinic. On Septem-
ber 30, 2002 the total number of patients, both on short
and long term treatment, registered in the outpatient
clinic was 998. In addition, there were 57 patients moni-
tored by general practitioners. On November 1, 2002, the
population in the uptake area was 138 240 persons.
Therefore, the total prevalence of oral anticoagulant treat-
ment in the district was approximately 0.76%.
In the study by Jansson et al 1987–1990, the two most
common indications for anticoagulant treatment were
valvular heart disease (including mechanical valve pros-
thesis) and arterial thromboembolism [5]. In our study
the most common indication for treatment was atrial
fibrillation followed by mechanical heart valve prosthesis.
Arterial thromboembolism is no longer one of the main
indications (Table 1).
Mechanical heart valve prosthesis was present in 263
patients. Patient records of these patients were not exam-
ined, leaving 637 records to be found. We managed to
find 582 patient records. Some indications and the mean
target interval for these patients are presented in Table 2.
Patient records of 55 subjects could not be retrieved. For
these subjects some information was found through the
warfarin dosage system, treatment indications of there are
presented in Table 3. After evaluation of indications and
contraindications, treatment was discontinued in 90 of
the 582 patients due to dubious reasons for treatment or
too high risk. Basic facts on these patients are presented in
Table 4. Of these 90, the treatment of 23 patients was dis-
continued before the patient was invited for examination
and by a physician who was not involved in this study
(Table 5). All discontinuations, except one case that had
atrial fibrillation, were in accordance with the method of
re-evaluation. In four cases without a valid indication the
medication was continued either because the patient or
the patient's physician strongly opposed the discontinua-
tion of warfarin treatment.
Of all INR values recorded, using a cross-section method,
11.4% were below 2.0 and 15.2% above 3.0 in all long-
term treated patients. For the subgroups continuously
treated patients with mechanical valve prosthesis, atrial
fibrillation, other indications and those with record miss-
ing the percentages were 7.0 and 22.7, 12.5 and 12.5, 13.7
and 12.0, and 16.1 and 11.3, respectively. Using a cumu-
lative method for the period from January 1, to December
31, 2002, the percentages of patients in the total group,
including short-term treatments that were outside the
individual target intervals were higher, as well as the per-
centages outside INR 2.0–3.0 (Tables 6 and 7).
Discussion
The total prevalence of 0.76% oral anticoagulant treat-
ment in the reception area of the oral anticoagulant out-
patient clinic was slightly lower than that reported,
around 0.8% reported in Sweden in general [1] and in
Denmark [2]. The population in the uptake area is young
as compared with the rest of Sweden, 33% of the popula-
tion was under 25 years of age, and 67% of the population
was less than 50 years of age, as compared with 30% and
63% respectively, in the total Swedish population. We
have not found any studies on continuous oral anticoag-
ulant treatment to compare with our results.
Table 5: Reasons for discontinuation of oral anticoagulant 
treatment.
Reason n %
Lack of indication 46 51
Too high risk 21 23
Discontinued by physician outside the study 23 26
Total 90 100
Table 4: Basic facts on patients whose treatment was continued vs. those whose treatment was discontinued.
Continued (n = 492) Discontinued (n = 90)
Mean (SD) Min Max Mean (SD) Min Max p
Age on October 15, 2002 (years) 72.4 (11.0) 20.4 94.7 71.2 (15.1) 20.6 92.6 0.370
Age at start of treatment (years) 68.2 (11.8) 17.2 89.1 66.1 (16.1) 13.7 89.7 0.149
Duration of treatment (years) 4.2 (3.6) 0.0 23.5 5.1 (4.5) 0.1 19.0 0.044
Mean target (INR) 2.5 (0.1) 1.7 3.2 2.5 (0.1) 1.7 3.2 0.249Thrombosis Journal 2005, 3:20 http://www.thrombosisjournal.com/content/3/1/20
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A high number of patients with dubious indications and/
or unacceptably high risk for treatment were found. The
reason for this may be the fear of discontinuing anticoag-
ulant medication. Those patients or their physicians may
prefer the risk of a bleeding complication to the risk for a
thromboembolic event. In addition, valid indications for
oral anticoagulant treatment have changed, and the signif-
icance of coagulopathies may have been under- or overes-
timated in the past. This may also be the case for other
indications. It takes time for new information to be imple-
mented in everyday medical practice. In some cases, the
patient or physician prefer to continue treatment despite
lack of indication; this reflects some of the difficulties in
routine oral anticoagulant monitoring.
A possible explanation for the high number of patients on
questionable oral anticoagulant treatment may be that
yearly re-evaluation is not always done due to lack of
resources. Sometimes it may not be obvious who is in
charge of the patient's oral anticoagulant treatment. In
many cases the re-evaluation is made by the patient's pri-
mary health care doctor who doesn't always have access to
the reasons for initiating the treatment or information
about possible risk factors.
The change in indications as compared with the study
done in 1987–1990 is striking (Table 1). Arterial throm-
bosis is no longer one of the main indications for oral
anticoagulant therapy. A series of clinical trials that began
in the mid-1980s provided substantial evidence for the
effectiveness of warfarin in prevention of stroke in
patients with atrial fibrillation [6-11]. The change may
reflect the increasing awareness of this fact.
The most common target treatment range in this study
was INR 2.1–3.0. After the completion of the study the tar-
get range had been changed to 2.0–3.0 in most of these
cases. In a study by Samsa et al, 45.0–66.8% of the INR
values in atrial fibrillation patients were outside the inter-
val 2.0–3.0 [12]. In our study only 33.2% of all INR values
during 2002 were outside this interval. In 1987 and 1990
Jansson et al found that less than 20% of the INR values
at the oral anticoagulant clinic at Umeå University Hospi-
tal were outside the desired treatment interval 2.1–4.2
during that time period [5]. That was a much broader
interval than we use nowadays. They also excluded
patients whose observation time was too short, i.e., less
than five INR values. We did not exclude any patients in
our study due to short observation time. We also had sev-
eral patients with actual target intervals different from the
most common target interval 2.1–3.0. We therefore
believe that the treatment quality in our study was at least
as good as it was in the study by Jansson et al [5]. In that
study PT ratio was used, but comparison is possible
because our laboratory was responsible for all the analy-
ses, using the same method principle (Owren), with the
same reagents thus enabling us to calculate the INR values
properly.
There has been consensus on the target range 2.0–3.0 in
atrial fibrillation and also in most of the other indications
[13,14]. Some patients, especially those with mechanical
heart valve prostheses, have a higher target INR. This was
seen especially among those whose treatment started a
long time ago (data not shown). Some elderly people
have lower target treatment range than INR 2.1–3.0. There
is still a debate about the benefits and disadvantages of
low-dose warfarin treatment after deep venous thrombo-
sis [15-17]. In some cases a lowering of the treatment
Table 7: Number of INR samples during 2002 <2.0, 2.0–3.0 and <3.0
2002 INR <2.0 n (%) INR 2.0–3.0 n (%) INR >3.0 n (%)
January-March 1032 (16.5) 4093 (65.4) 1137 (18.2)
April-July 1026 (16.9) 4040 (66.4) 1018 (16.7)
August-September 1033 (16.7) 4185 (67.5) 980 (15.8)
October-December 1047 (16.8) 4232 (68.0) 944 (15.2)
Total 4138 (16.7) 16550 (67.2) 4079 (16.5)
Table 6: Number of INR samples during 2002 under, within and over the patient's personal target interval
2002 Under personal interval n (%) Within personal interval n (%) Over personal interval n (%)
January-March 1274 (20.3) 3863 (61.7) 1125 (18.0)
April-July 1257 (20.7) 3791 (62.3) 1036 (17.0)
August-September 1299 (21.0) 3894 (62.8) 1005 (16.2)
October-December 1273 (20.5) 397 (63.8) 977 (15.7)
Total 5103 (20.6) 15521 (62.7) 4143 (16.7)Thrombosis Journal 2005, 3:20 http://www.thrombosisjournal.com/content/3/1/20
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range might be an optimal alternative. In others it may be
just an excuse for not discontinuing oral anticoagulant
treatment. More studies are needed on this issue.
This study had some limitations: The prevalence of anti-
coagulant treatment may have been slightly underesti-
mated since a few patients are treated through primary
health care centres. However these patients are very few (n
= 57). Complete patient records could not be found for 55
patients (8.6%) in the study, not counting those with
mechanical heart valve prostheses. However, treatment
indications of these patients were similar to those with
records found. It can not be excluded that some bias of the
results may be caused by the patients with missing
records. The number of missing records will be lower
when computerised medical records are introduced. How-
ever, in studies based on medical records, drop out rates
higher than we found are common. The difficulty of
retrieving medical records in a medical setting has been
described [18]. In that study up to 30% of the patient
records were unavailable at the time of the medical con-
sultation. Some thromboembolic events in the past may
have escaped our attention because they had been treated
at another hospital.
There is a problem with the oldest of the old: The risk of
thromboembolic events rises with age. So do the prob-
lems with maintaining the treatment within the target
interval, and the risk of bleeding complications [19,20].
Attempts to prospectively assess risk factors in warfarin
treatment have been made [21]. In medical practice, risk
assessment is often subjective in the absence of accurate,
objective, easy-to-use protocols. The balance between the
risk for a thromboembolic event and the risk for a bleed-
ing complication in this group is still unclear and further
studies need to be done on this issue.
Thrombin inhibitors are a new group of drugs on the mar-
ket. The fear of liver complications when using these drugs
may prevent the wider usage of these drugs for many
years, leaving anti vitamin K drugs an important option
for secondary thrombosis prevention [22].
Conclusion
In patients on oral anticoagulant therapy, re-evaluation of
indications and risks resulted in a substantial number of
treatment withdrawals. Treatment should be re-consid-
ered once a year, due to the rapid development of knowl-
edge in the field of thrombosis risk factors. The
indications for oral anticoagulant treatment have
changed: Atrial fibrillation is now the most common indi-
cation while arterial thrombosis is no longer a common
reason.
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